These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

308 related items for PubMed ID: 14517844

  • 1. Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma.
    Viard-Leveugle I, Veyrenc S, French LE, Brambilla C, Brambilla E.
    J Pathol; 2003 Oct; 201(2):268-77. PubMed ID: 14517844
    [Abstract] [Full Text] [Related]

  • 2. Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer.
    Müllauer L, Mosberger I, Grusch M, Rudas M, Chott A.
    J Pathol; 2000 Jan; 190(1):20-30. PubMed ID: 10640988
    [Abstract] [Full Text] [Related]

  • 3. In vivo expression of soluble Fas and FAP-1: possible mechanisms of Fas resistance in human hepatoblastomas.
    Lee SH, Shin MS, Lee JY, Park WS, Kim SY, Jang JJ, Dong SM, Na EY, Kim CS, Kim SH, Yoo NJ.
    J Pathol; 1999 Jun; 188(2):207-12. PubMed ID: 10398166
    [Abstract] [Full Text] [Related]

  • 4. Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer.
    Gratas C, Tohma Y, Barnas C, Taniere P, Hainaut P, Ohgaki H.
    Cancer Res; 1998 May 15; 58(10):2057-62. PubMed ID: 9605741
    [Abstract] [Full Text] [Related]

  • 5. Fas (Apo-1, CD95) receptor expression in childhood astrocytomas. Is it a marker of the major apoptotic pathway or a signaling receptor for immune escape of neoplastic cells?
    Bodey B, Bodey B, Siegel SE, Kaiser HE.
    In Vivo; 1999 May 15; 13(4):357-73. PubMed ID: 10586378
    [Abstract] [Full Text] [Related]

  • 6. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes.
    Gastman BR, Atarshi Y, Reichert TE, Saito T, Balkir L, Rabinowich H, Whiteside TL.
    Cancer Res; 1999 Oct 15; 59(20):5356-64. PubMed ID: 10537320
    [Abstract] [Full Text] [Related]

  • 7. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis.
    Ungefroren H, Voss M, Jansen M, Roeder C, Henne-Bruns D, Kremer B, Kalthoff H.
    Cancer Res; 1998 Apr 15; 58(8):1741-9. PubMed ID: 9563493
    [Abstract] [Full Text] [Related]

  • 8. Cholangiocarcinomas express Fas ligand and disable the Fas receptor.
    Que FG, Phan VA, Phan VH, Celli A, Batts K, LaRusso NF, Gores GJ.
    Hepatology; 1999 Dec 15; 30(6):1398-404. PubMed ID: 10573518
    [Abstract] [Full Text] [Related]

  • 9. Fas-activated apoptosis and apoptosis mediators in human trabecular meshwork cells.
    Agarwal R, Talati M, Lambert W, Clark AF, Wilson SE, Agarwal N, Wordinger RJ.
    Exp Eye Res; 1999 May 15; 68(5):583-90. PubMed ID: 10328972
    [Abstract] [Full Text] [Related]

  • 10. Induction of Fas-mediated apoptosis in a human renal epithelial cell line by interferon-gamma: involvement of Fas-mediated apoptosis in acute renal rejection.
    Akasaka Y, Ishikawa Y, Kato S, Ishii T, Masuda T, Fujita K, Yamada T, Kawamura S.
    Mod Pathol; 1998 Nov 15; 11(11):1107-14. PubMed ID: 9831209
    [Abstract] [Full Text] [Related]

  • 11. FasL:Fas ratio--a prognostic factor in breast carcinomas.
    Reimer T, Herrnring C, Koczan D, Richter D, Gerber B, Kabelitz D, Friese K, Thiesen HJ.
    Cancer Res; 2000 Feb 15; 60(4):822-8. PubMed ID: 10706087
    [Abstract] [Full Text] [Related]

  • 12. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma.
    Bennett MW, O'Connell J, O'Sullivan GC, Brady C, Roche D, Collins JK, Shanahan F.
    J Immunol; 1998 Jun 01; 160(11):5669-75. PubMed ID: 9605174
    [Abstract] [Full Text] [Related]

  • 13. Quantitation of Fas and Fas ligand gene expression in human ovarian, cervical and endometrial carcinomas using real-time quantitative RT-PCR.
    Das H, Koizumi T, Sugimoto T, Chakraborty S, Ichimura T, Hasegawa K, Nishimura R.
    Br J Cancer; 2000 May 01; 82(10):1682-8. PubMed ID: 10817504
    [Abstract] [Full Text] [Related]

  • 14. Expression of Bcl-2 in lung neuroendocrine tumours: comparison with p53.
    Wang DG, Johnston CF, Sloan JM, Buchanan KD.
    J Pathol; 1998 Mar 01; 184(3):247-51. PubMed ID: 9614375
    [Abstract] [Full Text] [Related]

  • 15. Overexpression of AML1 renders a T hybridoma resistant to T cell receptor-mediated apoptosis.
    Fujii M, Hayashi K, Niki M, Chiba N, Meguro K, Endo K, Kameoka J, Ito S, Abe K, Watanabe T, Satake M.
    Oncogene; 1998 Oct 08; 17(14):1813-20. PubMed ID: 9778047
    [Abstract] [Full Text] [Related]

  • 16. Expression of Fas (CD95) and FasL (CD95L) in human airway epithelium.
    Hamann KJ, Dorscheid DR, Ko FD, Conforti AE, Sperling AI, Rabe KF, White SR.
    Am J Respir Cell Mol Biol; 1998 Oct 08; 19(4):537-42. PubMed ID: 9761749
    [Abstract] [Full Text] [Related]

  • 17. Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer.
    O'Connell J, Bennett MW, O'Sullivan GC, Roche D, Kelly J, Collins JK, Shanahan F.
    J Pathol; 1998 Nov 08; 186(3):240-6. PubMed ID: 10211111
    [Abstract] [Full Text] [Related]

  • 18. The alteration of Fas receptor and ligand system in hepatocellular carcinomas: how do hepatoma cells escape from the host immune surveillance in vivo?
    Nagao M, Nakajima Y, Hisanaga M, Kayagaki N, Kanehiro H, Aomatsu Y, Ko S, Yagita H, Yamada T, Okumura K, Nakano H.
    Hepatology; 1999 Aug 08; 30(2):413-21. PubMed ID: 10421649
    [Abstract] [Full Text] [Related]

  • 19. Increased apoptosis of T cell subsets in aging humans: altered expression of Fas (CD95), Fas ligand, Bcl-2, and Bax.
    Aggarwal S, Gupta S.
    J Immunol; 1998 Feb 15; 160(4):1627-37. PubMed ID: 9469419
    [Abstract] [Full Text] [Related]

  • 20. Lymphocyte apoptosis induced by Fas ligand- expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes.
    Rabinowich H, Reichert TE, Kashii Y, Gastman BR, Bell MC, Whiteside TL.
    J Clin Invest; 1998 Jun 01; 101(11):2579-88. PubMed ID: 9616229
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.